eligibility_summary
Inclusion: 18–70, MSLN+ solid tumor, failed/no standard therapy, ≥1 evaluable lesion, tissue available, ECOG 0–1, life ≥3 mo, adequate organ function, contraception/consent. Exclusion: recent anticancer/immunosuppressive therapy or live vaccine, pregnancy/lactation, active HBV/HCV/HIV/EBV, unresolved toxicity, major surgery, CNS mets, serious cardiac/infectious/autoimmune/immunodeficiency/bleeding issues, prior transplant, prior anti‑MSLN or gene‑modified cells, recent trial/other malignancy, severe allergy, neuropsychiatric disorder.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: UCMYM802 Injection—an autologous cellular immunotherapy (biologic) comprising anti-mesothelin CAR-T cells. T cells are engineered ex vivo using circular mRNA to transiently express a chimeric antigen receptor targeting mesothelin (no genomic integration). Dosing: IV infusions weekly ×4, dose-escalation 1×10^8 to 2×10^9 cells. Mechanism of action: CAR binding to mesothelin on tumor cells drives HLA-independent T-cell activation, leading to cytotoxic killing (perforin/granzyme), cytokine release, and proliferation via CAR signaling. Targets: Mesothelin (MSLN)–positive malignant solid tumors (e.g., mesothelioma, pancreatic, biliary, ovarian, colorectal, breast). Pathways engaged: CAR-mediated TCR signaling (CD3ζ-based activation), downstream T-cell effector functions, and tumor cell apoptosis.